All of the best-performing club stocks so far in 2024 turned out to be big winners in 2023. This suggests investors haven't completely abandoned last year's strategy, at least for now. Artificial intelligence chipmaker Nvidia, cybersecurity provider Palo Alto Networks and pharmaceutical giant Eli Lilly were the club's biggest gainers in early 2024. Through Thursday's close, shares had risen 10.7%, 9.7%, and 9.06%, respectively. S&P500. All three companies closed at record highs on Thursday. This progress builds on last year's outstanding performance. Nvidia has more than tripled in value to become the top not only club stock, but also the entire S&P 500 in 2023. Meanwhile, Palo Alto Networks soared nearly 112% last year, becoming the first cybersecurity company to reach its highest level. Market capitalization is $100 billion. Eli Lilly rose his 59.3%, marking his seventh consecutive year of gains. The Nvidia, Eli Lilly and Palo Alto Networks stock trades come as Wall Street's rotation into a broader basket of stocks in late 2023 subsides. Eli Lilly and Palo Alto Networks, in particular, underperformed in the final weeks of the year, ending December in the red. Of course, it is difficult to draw sweeping conclusions from the strength of early 2024. There's no guarantee that what worked for him in his first two weeks of the year will continue to work as the calendar progresses. That's especially true given that the news flow for these three winners in January was littered with no new financial revelations. Eli Lilly's next quarterly results are scheduled to be released on February 6th, along with 2024 guidance. Nvidia and Palo Alto Networks are expected to report in late February. At the same time, the fundamental reasons for continuing to invest in these three high-quality companies remain compelling. It's his Nvidia's position as a leading AI chip maker, Eli Lilly's fast-growing obesity and diabetes drugs, and the robust cybersecurity demand that underpins Palo Alto's prospects. In the case of Nvidia and Palo Alto, their decisions to lock in profits last week after delivering massive results in 2023 gave them the confidence to ride out their stock price. Eli Lilly recorded a profit in September. Gains never hurt. NVDA 3M Mountain Nvidia 3 Months Nvidia's best trade of the year took place on Monday, when the stock rose 6.4% on a day filled with investor excitement over presentations at the Consumer Electronics Show in Las Vegas. At this event, Nvidia announced his three new graphics processing units (GPUs) designed to run generated artificial AI applications on consumer laptops and professional workstations. We are optimistic that the market for so-called AI PCs will eventually prove significant and will motivate people to buy new machines, but at this stage this is very early days. category. Additionally, the majority of Nvidia's revenue now comes from AI chips that go into data centers, a much more lucrative market than consumer PCs. The analyst community remains optimistic about his Nvidia in January. Semiconductor analysts at multiple research firms, including Mizuho, Trust, and Oppenheimer, call Nvidia a top candidate in the field. And last week, Bank of America said NVIDIA could generate $100 billion in free cash flow over the next two years, giving the company the firepower it needs to invest in new growth initiatives. said that it can be done. LLY 3M Mountain Eli Lilly 3 Months Eli Lilly was positive on 6 of his 8 trading days in 2024, including Thursday's session. Shares soared more than 4% on January 3, the biggest trading session of the year. That day, Bank of America pharmaceutical analysts named Lilly as their favorite idea of the year, saying the company is developing a new technology in the fast-growing field of obesity and diabetes drugs known as GLP-1. It argued that it was in a better position to deal with competition. The promise that GLP-1 will drive earnings growth in the coming years is at the heart of our investment thesis for Eli Lilly. Morgan Stanley analysts on Thursday raised their 2024 sales forecast for Eli Lilly's recently approved weight-loss drug Zepbound to $5.5 billion from $3 billion. The company also raised its price target for the company from $727 to $763 per share, implying a 20% upside from current levels. Eli Lilly also laid out an encouraging long-term vision at the influential JPMorgan Healthcare Conference on Tuesday, and last week launched a direct-to-consumer initiative to increase access to Zepbound. PANW 3M Mountain Palo Alto Networks 3 Months Palo Alto Networks stock begins his 2024 on a rough note, falling in each of his first four trading days amid seven sessions of deep declines that continue through December Did. However, this week's performance has been much brighter, with Monday's 2.32% gain being the “worst” trade to date. The all-time high came on Wednesday, when the stock soared more than 5% to a record closing price of $316.09 per share at the time. Wednesday's rise comes after Morgan Stanley raised its price target for Palo Alto from $304 to $375 per share. Analysts said 2024 is set to be a “momentous year” for the cybersecurity industry, and Palo Alto Networks is the frontrunner in the space. (Jim Cramer's Charitable Trust is long NVDA, LLY, and PANW. See here for a complete list of stocks.) As a subscriber to Jim Cramer's CNBC Investment Club, Jim trades Receive trade alerts before you make them. After Jim sends a trade alert, he waits 45 minutes before buying or selling stocks in a charitable trust's portfolio. If Jim talks about a stock on his CNBC TV, he will wait 72 hours before executing the trade after issuing a trade alert. The above investment club information is subject to our Terms of Use and Privacy Policy, as well as our disclaimer. No fiduciary duties or obligations exist or arise from your receipt of information provided in connection with the Investment Club. No specific results or benefits are guaranteed.
Pedestrians pass through the Wall Street subway station near the New York Stock Exchange (NYSE) on Monday, June 27, 2022 in New York, USA.
Bloomberg | Bloomberg | Getty Images
All of the best-performing club stocks so far in 2024 turned out to be big winners in 2023. This suggests investors haven't completely abandoned last year's strategy, at least for now.
